To access this element change to forms mode OFF
Grant Award View - GA268498
Development of antiviral RNA therapeutics targeting SARS-CoV-2 infection
GA ID:
GA268498
Agency:
Department of Health and Aged Care
Approval Date:
19-Jun-2022
Publish Date:
4-Oct-2022
Category:
Medical Research
Grant Term:
19-Jun-2022 to 31-May-2024
Value (AUD):
$998,339.60
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 21/22 1.1 Health Policy Research and Analysis
Grant Program:
MRFF Research Grants
Grant Activity:
Development of antiviral RNA therapeutics targeting SARS-CoV-2 infection
Purpose:
There is an urgent need for antiviral treatments for COVID-19 infection due to evolving vaccine resistance and lack of adequate immune responses. This project develops direct acting antiviral RNA therapeutics to prevent and treat COVID-19 infection. The antiviral RNA will be delivered by inhaling nanoparticles that carry the therapeutic directly to targeted respiratory sites. The project will also provide pre-clinical data for accelerated translation to human proof of concept clinical trials.
GO ID:
GO Title:
MRFF – CRR – 2021 COVID-19 Treatment Access and Public Health Activities Grant Opportunity
Internal Reference ID:
2022/MRF2017698
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Kensington
Town/City:
Kensington
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, NETHERLANDS